Clal Biotechnology reported ILS121.41M in Equity Capital and Reserves for its fiscal quarter ending in December of 2023.





Equity Capital And Reserves Change Date
aTyr Pharma USD 80.24M 5.58M Sep/2025
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 43.83M 6.43M Sep/2025
RedHill Biopharma USD -4.41M 271K Jun/2025